ストックスクリーナーアプリを入手
193.76
2.26%
4.29
Biogen Inc (BIIB) 最新ニュース
Biogen Inc. (NASDAQ: BIIB) Navigates Alzheimer’s Drug Trajectory After Leqembi Updates - foreignpolicyjournal.com
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Biogen Faces Trial Setbacks And Probes That Reframe Neuro Pipeline Risks - Yahoo Finance UK
Biogen and Denali Halt Development of BIIB122 After Phase 2b LUMA Study Fails in Early Parkinson’s Disease - Minichart
Parkinson’s drug from Biogen, Denali comes up short - BioPharma Dive
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails - Yahoo Finance
Biogen Inc. (BIIB) Securities Fraud InvestigationLevi & Korsinsky - PR Newswire
Biogen (BIIB) and Denali (DNLI) Halt Development of BIIB122 Afte - GuruFocus
Biogen Stock Slides After Trial Miss, but Analysts Stay Bullish - Investing.com
Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish - MarketBeat
Biogen, Denali pull plug on Parkinson’s program after mid-stage flop - BioSpace
Biogen, Denali to drop Parkinson’s therapy (BIIB:NASDAQ) - Seeking Alpha
Denali Therapeutics and Biogen discontinue BIIB122 after Phase 2b LUMA misses endpoints - TradingView
Biogen, Denali scrap Parkinson’s candidate after Phase IIb miss - The Pharma Letter
Biogen, Denali axe LRRK2 inhibitor in idiopathic Parkinson’s after mid-stage miss - FirstWord Pharma
Biogen stock (US09062X1037): Parkinson’s drug setback hits pipeline - AD HOC NEWS
Parkinson’s trial setback: Biogen, Denali halt BIIB122 program, await 2027 data - Stock Titan
Biogen and Denali Therapeutics Halt BIIB122 Development After Tr - GuruFocus
Biogen and Denali halt BIIB122 development after Phase 2b Parkinson's study fails to meet endpoints - Pluang
BIIB, DNLI Stocks Edge Lower After Hours: Parkinson’s Drug Misses Key Goals In Trial - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc.BIIB - PR Newswire
Biogen, Denali scrap Parkinson’s drug after failure in mid-to-late stage study - WNWN-FM
Biogen (BIIB) Halts Development of BIIB122 After Phase 2b Study Results - GuruFocus
Biogen, Denali discontinue Parkinson’s drug after trial fails By Investing.com - Investing.com Australia
[8-K] Denali Therapeutics Inc. Reports Material Event - Stock Titan
Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study - Reuters
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease - Biogen
Biogen Patent Suit Targets Somerset’s Copy of Spinraza Therapy - Bloomberg Law News
Apellis soars on Biogen deal as biopharma index trails the market - BioWorld News
(BIIB) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Biogen stock (US09062X1037): FDA decision keeps investors focused - AD HOC NEWS
Biogen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Apellis Shares Disappear After Biogen’s $5.6 Billion Buy—One Play Left - TechStock²
Levi & Korsinsky Announces Investigation of Securities Claims Against Biogen Inc. (BIIB) - GlobeNewswire
Are Wall Street Analysts Bullish on Biogen Stock? - Yahoo Finance
How Biogen’s Diranersen Alzheimer’s Bet Will Impact Biogen (BIIB) Investors - simplywall.st
Ionis Rises As Diranersen Phase 2 Spurs Biogen Registrational Plans - simplywall.st
Biogen stock (US09062X1037): Alzheimer data and Q1 earnings keep focus on biotech transition - AD HOC NEWS
Biogen Earnings Call Signals Confident, Investment-Heavy Transition - TipRanks
BIIB Investor Alert: Levi & Korsinsky Investigates Biogen Inc. (BIIB) for Potential Securities Fraud - Business Wire
Biogen Inc (BIIB) Stock Price, Trades & News - GuruFocus
Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout - Proactive financial news
Biogen stock (US09062X1037): Alzheimer’s focus after Leqembi setback and pipeline updates - AD HOC NEWS
Biogen Inc. stock underperforms Thursday when compared to competitors - MSN
Biogen’s Apellis Deal And Alzheimer’s Trial Shift Focus Beyond Price - Yahoo Finance
Investigation launched into Biogen after Alzheimer's drug trial misses key goal, stock drops sharply. - Pluang
Biogen shares drop 6.4% after Phase 2 trial misses primary endpoint for diranersen - Pluang
Biogen Faces Legal Scrutiny After Diranersen Trial Results, Stoc - GuruFocus
Assessing Biogen (BIIB) Valuation After Recent Share Price Momentum And Earnings Expectations - simplywall.st
Biogen completes acquisition of Apellis Pharmaceuticals - Ophthalmology Times
BIIB SHAREHOLDER INVESTIGATION: SueWallSt Investigates Biogen Inc. for Possible Securities Law Violations - PR Newswire
Wedbush Maintains Biogen(BIIB.US) With Hold Rating, Maintains Target Price $196 - Moomoo
Which Is a Better Investment, Ascendis Pharma A/S or Biogen Inc. Stock? - AAII
Rare Disease Therapeutics Market 2025-2033 | Market Growth - openPR.com
Biogen Inc. (BIIB): Investor Outlook With A Potential 13.64% Upside - DirectorsTalk Interviews
Neuromuscular Disease Therapeutics Market to Reach USD 45.62 - openPR.com
BIIB Stock Price Prediction 2025-2026 | Biogen Inc Forecast - 24/7 Wall St.
Biogen Inc. stock (US09062X1037): Goldman Sachs lifts target after strong Q1 and Leqembi momentum - AD HOC NEWS
Biogen Inc stock (US09062X1037): Goldman Sachs lifts target after strong Q1 and Leqembi momentum - AD HOC NEWS
Goldman Sachs sets new Biogen stock price target on bold Alzheimer’s bet - thestreet.com
0.19%
2.96%
大文字化:
|
ボリューム (24 時間):